Richard Kollender Net Worth

Richard Kollender biography

Richard S. Kollender serves as Chief Operating Officer of the Company. He previously served as a Class II director of our board of directors from March 2015 until September 2019, and was Chairman of the audit committee and a member of the compensation committee. Since January 2011, he has served as a Partner and Executive Manager of Quaker Partners Management, LP, a healthcare investment firm, which he initially joined in 2003, and was promoted to Partner in 2005. In addition, from August 2016 through September 2018, Mr. Kollender served as Chief Business Officer and Chief Financial Officer of Rapid Micro Biosystems, a Quaker Partners’ portfolio company, where he continues to serve on the board of directors. Mr. Kollender held positions in sales, marketing and worldwide business development at GlaxoSmithKline (“GSK”), and served as investment manager at S.R. One, the corporate venture capital arm of GSK. Mr. Kollender holds a B.A. in accounting from Franklin and Marshall College and an M.B.A. and a certificate degree in the Graduate Program in Health Administration and Policy, both from the University of Chicago, and practiced as a certified public accountant for six years at public accounting firms including KPMG.

What is the salary of Richard Kollender?

As the Chief Operating Officer of Strongbridge Biopharma plc, the total compensation of Richard Kollender at Strongbridge Biopharma plc is $173,639. There are 5 executives at Strongbridge Biopharma plc getting paid more, with Frederic Cohen having the highest compensation of $1,093,830.

What's Richard Kollender's mailing address?

Richard's mailing address filed with the SEC is 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE, PA, 19053.

Insiders trading at Strongbridge Biopharma plc

Over the last 7 years, insiders at Strongbridge Biopharma plc have traded over $0 worth of Strongbridge Biopharma plc stock and bought 2,670,648 units worth $8,846,818 . The most active insiders traders include Associates, L.L.C.Caxton Co..., Garheng Kong y Jeffrey W Sherman. On average, Strongbridge Biopharma plc executives and independent directors trade stock every 89 days with the average trade being worth of $593,478. The most recent stock trade was executed by David N Gill on 24 September 2020, trading 8,000 units of SBBP stock currently worth $17,040.

What does Strongbridge Biopharma plc do?

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing's syndrome, and veldoreotide extended release, a preclinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company's rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.

Strongbridge Biopharma plc executives and stock owners

Strongbridge Biopharma plc executives and other stock owners filed with the SEC include:

• Frederic Cohen,
  Chief Medical Officer
• Robert Lutz,
  Chief Financial Officer
• John Johnson,
  Chief Executive Officer
• Marten Steen,
  Independent Director
• Garheng Kong,
  Lead Independent Director
• Richard Kollender,
  Chief Operating Officer
• Hilde Steineger,
  Independent Director
• Jeffrey Sherman,
  Independent Director
• David Gill,
  Independent Director
• Stephen Long,
  Secretary, Chief Legal Officer
• Scott Wilhoit,
  Chief Commercial Officer
• A Brian Davis,
  Chief Financial Officer
• Matthew Pauls,
  President & CEO
• Fredric J. Cohen,
  Chief Medical Officer
• Associates, L.L.C.Caxton Co...,